In COVID-19 clinical update #89, Dr. Griffin reviews upcoming meeting on FDA emergency use authorization for molnupiravir, 25% of US cases in children, reinfection associates with presence of antibodies, national surveillance for acute flaccid myelitis in the US, and monoclonal antibody treatment of infection in vaccinated, high-risk individuals. Hosts: Daniel Griffin and Vincent Racaniello Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Scott Hammer on TWiV 52 Meeting for molnupiravir EUA (FDA) SARS-CoV-2 reinfection associates with antibodies (Clinical Inf Dis) AFM surveillance in US (CDC) Monoclonal antibody treatment in high-risk patients (J Inf Dis) Letters read on TWiV 831 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]